首页|不同剂量芬吗通对更年期综合征患者临床症状改善及脂代谢、内分泌功能影响

不同剂量芬吗通对更年期综合征患者临床症状改善及脂代谢、内分泌功能影响

扫码查看
目的:探讨不同剂量芬吗通对更年期综合征患者脂代谢及内分泌功能的影响.方法:选取2021年8月—2023年5月在本院治疗的更年期综合征患者106例,随机分为两组各53例,分别给予常规剂量芬吗通(常规组)、低剂量芬吗通(低剂量组).比较两组的更年期综合征症状评分(Kuppeman)评分、血脂、性激素及不良反应.结果:治疗后两组Kupperman评分下降,且常规组(8.61±2.13分)低于低剂量组(9.57±2.24分)(P<0.05);两组治疗后总胆固醇、甘油三酯、低密度脂蛋白胆固醇均下降,高密度脂蛋白胆固醇均上升(P<0.05),但两组比较无差异(P>0.05)o治疗后雌二醇均上升但常规组(40.58±3.25ng/L)高于低剂量组(34.16±3.12ng/L),促卵泡生成素、促黄体生成素水平均下降但常规组(37.52±4.28 mU/ml、21.04±2.68mU/ml)低于低剂量组(44.67±4.86 mU/ml、25.14±2.77mU/ml)(均P<0.05).不良反应发生率常规组(17.0%)与低剂量组(9.4%)无差异(P>0.05).结论:不同剂量的芬吗通均可有效改善更年期综合征患者的临床症状、脂代谢及内分泌紊乱,但常规剂量的芬吗通应用疗效更佳且未增加不良反应发生风险.
Effects of the different doses of femostonon for treating patients with menopausal syndrome on their lipid metabolism and endocrine function
Objective:To investigate the effects of the different doses of femostonon for treating patients with menopa-usal syndrome on their lipid metabolism and endocrine function.Methods:106 patients with menopausal syndrome treated in hospital were selected and were randomly divide into two groups(53 cases in each group)from August 2021 to May 2023.The patients in group A were given the conventional dose of femoston for treatment and the patients in group B were given the low dose of femoston for treatment.The score of Kuppeman menopause rating scale,the levels of the blood lipids and sex hormones,and the adverse reactions rate of the patients were compared between two groups.Results:The Kupperman score of the patients in both groups had decreased significantly,and which(8.61±2.13 points)of the patients in group A were significantly lower than that(9.57±2.24 points)of the patients in group B(P<0.05).The levels of the total cholesterol,triglyceride,low density lipoprotein cholesterol of the patients in the two groups after treatment had decreased significantly,but the high-density lipoprotein cholesterol level of the patients in the two groups after treatment had increased significantly(P<0.05),but all of which of the patients had no significant differences between the two groups(P>0.05).After treatment,the estradiol level of the patients in both groups had increased significantly,but which(40.58±3.25ng/L)of the patients in group A was significantly higher than that(34.16±3.12ng/L)of the patients in group B.The levels of follicle-stimulating hormone(37.52±4.28 mU/ml)and luteinizing hormone(21.04±2.68mU/ml)of the patients in group A were significantly lower than those(44.67±4.86 mU/ml and 25.14±2.77mU/ml)of the patients in group B(all P<0.05).The incidence of adverse reactions(17.0%)of the patients in group A had no significantly different from that(9.4%)of the patients in group B(P>0.05).Con-clusion:The different doses of femostonon for treating patients with menopausal syndrome can effectively improve their clinical symptoms,abnormal lipid metabolism and endocrine disorders,but the conventional dose of femoston has the better efficacy without increasing the risk of adverse reactions.

Menopausal syndromeFemostonConventional doseLow doseKupperman scoreEndocrineLipid metabolismAdverse reaction

郭蜜甜、景志英、张继

展开 >

河南省郑州市第七人民医院(450006)

更年期综合征 芬吗通 常规剂量 低剂量 更年期综合征症状评分 内分泌 脂代谢 不良反应

2019年度河南省医学科技攻关计划联合共建项目

LHGJ20191116

2024

中国计划生育学杂志
国家人口计生委科学技术研究所

中国计划生育学杂志

CSTPCD
影响因子:1.759
ISSN:1004-8189
年,卷(期):2024.32(9)